Loading clinical trials...

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors | Clinical Trials | Clareo Health

COMPLETEDPHASE1/PHASE2

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

NCT04349267•Bristol-Myers Squibb

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Participants must have histologic confirmation of advanced (metastatic, recurrent, and/or unresectable) squamous cell carcinoma of the head and neck (SCCHN), nonsmall cell lung cancer (NSCLC), or renal cell cancer (RCC) with measurable disease per RECIST 1.1
•Participants expected to have received standard of care therapies including an available PD-(L)1 inhibitor
•Eastern cooperative oncology group performance status of 0 or 1
•Women of childbearing potential must agree to follow methods of contraception

Exclusion Criteria

•Participants with active, known or suspected autoimmune disease
•Participants with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications
•Uncontrolled or significant cardiovascular disease
•History of or with active interstitial lung disease or pulmonary fibrosis
•Prior participation in anti-natural killer cell receptor (anti-NKG2A) clinical study
•History of allergy or hypersensitivity to study drug components

Locations (8)

Local Institution - 0028

Sioux Falls, South Dakota, United States

Local Institution - 0001

Germantown, Tennessee, United States

Local Institution - 0014

Edmonton, Alberta, Canada

Local Institution - 0011

Vancouver, British Columbia, Canada

Local Institution - 0004

Toronto, Ontario, Canada

Local Institution - 0005

Montreal, Quebec, Canada

Local Institution - 0013

Ottawa, Canada

Local Institution

Mexico City, Mexico City, Mexico

Key Dates

Start Date

July 14, 2020

Primary Completion Date

August 22, 2024

Completion Date

August 22, 2024

Last Updated

December 17, 2025

Enrollment

ACTUAL participants

Conditions

Advanced Solid Tumor

Interventions

BMS-986315

BIOLOGICAL

nivolumab

BIOLOGICAL

cetuximab

BIOLOGICAL

A Study of PYX-201 in Advanced Solid Tumors

NCT05720117

Solid TumorAdvanced Solid Tumor

View study

RECRUITINGPHASE1/PHASE2

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

NCT06898450

Advanced Solid Tumors CancerMSI-H Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 17, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

Inclusion Criteria

Exclusion Criteria

A Study of PYX-201 in Advanced Solid Tumors

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

A Study of ASP1002 in Adults for Treatment of Solid Tumors

A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors